Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT01017926
First received: November 20, 2009
Last updated: August 5, 2010
Last verified: August 2010
  Purpose

The purpose of this study is to compare the bioavailability of two oral formulations of Triazolam in healthy volunteers, in order to determine that they are bioequivalent.


Condition Intervention Phase
Healthy Volunteers
Drug: Triazolam
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia & Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Volunteers Under Fasting Conditions

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Establish Cmax, Tmax, elimination half life, area below the curve from zero to t, and area below the curve from zero to infinity (ABC 0-∞) of the two formulations of Triazolam in tablets [ Time Frame: Day 1 and two after dosage is taken ] [ Designated as safety issue: Yes ]
  • Statistically compare the bioavailability of the pharmaceutical formulations of Triazolam studied, to establish or rule out the existence of bioequivalence [ Time Frame: Six to eight weeks after completing the study, a final report will be prepared. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Investigate the safety of both preparations based on the record of adverse events on completing both study periods [ Time Frame: Up to 3 days after the 2nd period ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 26
Study Start Date: August 2010
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Triazolam Reference Arm
There will be a clearance period of at least 3 days between the two phases of the study.
Drug: Triazolam
Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
Experimental: Triazolam Trial Arm Drug: Triazolam
Tablets, 0.25 mg, single-dose, 1 period of 3 three days.

Detailed Description:

The bioequivalence trial of triazolam is due to change in manufacture site.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Only healthy volunteers, between the ages of 18 and 40 years, will be included.
  • Subjects' body mass index must be between 19-27.
  • Volunteers must be in good health, as determined by the results of a complete clinical history prepared by doctors at the clinical research site and laboratory tests performed at certified clinical laboratories.
  • Volunteers must agree to use at least two birth control methods (except hormonal contraceptives) from the first dose of the study drug and for up to 28 days after the last dose. (acceptable methods are surgically definitive sterilization, menopause, barrier methods such as condoms and diaphragm, and spermicidal gels/foams)
  • The limits of variation permitted within normality at the screening visit will be: blood pressure (seated) 90 to 130 mm Hg systolic and 60 to 90 mm Hg diastolic, heart rate between 55 and 100 beats per minute and respiratory rate between 14 and 20 respirations per minute.
  • The laboratory and cabinet tests required to include subjects in the studio will be: 1) Hematology: hemoglobin, hematocrit, total white blood cell count with differential, and platelet count, 2) 27-element blood chemistry, 3) Markers for hepatitis B and C. 4) Detection of HIV, 5) General urinalysis, 6) Drug abuse test in both study periods, 7) Qualitative pregnancy test in both study periods (if applicable) , 8) Electrocardiogram. (pre-screening/recruitment)

Exclusion Criteria:

  • Subjects in whom any alteration is detected in their vital signs recorded at the screening of volunteers.
  • Volunteers who fail to comply with the established criteria for inclusion.
  • Volunteers with antecedents of cardiovascular, renal, hepatic, muscular, metabolic, and gastrointestinal disorders, including constipation; neurological, endocrine, and hematopoietic disorders; or any kind of anemia, asthma, mental illness, or other organic abnormalities, as well as those who have suffered a muscular traumatism within 21 days before the study.
  • Volunteers who require any medication over the course of the study, aside from the drug being studied.
  • Volunteers with antecedents of dyspepsia, gastritis, esophagitis, and duodenal or gastric ulcers.
  • Volunteers who have been exposed to known hepatic enzyme inductors or inhibitors or have taken potentially toxic drugs within 30 days before the start of the study.
  • Volunteers who have received any medication within 14 days or 5 half lives (whichever is longer) before the start of the study.
  • Volunteers who have been hospitalized for any problem within seven months before the start of the study.
  • Subjects who have received investigational drugs within 60 days prior to the study.
  • Subjects allergic to any antibiotic and/or non-steroidal antiinflammatory analgesics.
  • Subjects who have consumed alcohol or xanthine containing beverages (coffee, tea, cocoa, chocolate, mate, colas) or have consumed charcoal broiled foods or grapefruit juice within one week before the start of the study and until the last sample is taken.
  • Subjects who have donated or lost 450 mL or more of blood within 60 days before the start of the study.
  • History of regular consumption of alcohol exceeding 14 drinks/week (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of liquor within 6 months before the screening visit.
  • Excessive use of products containing tobacco or nicotine, equivalent to 5 cigarettes per day.
  • Female volunteers with positive results on the pregnancy test or in lactation.
  • Volunteers who require a special diet for any reason, for example vegetarians.
  • Disability of any kind that prevents the volunteer from understanding the nature, purpose, and potential consequences of the study.
  • Evidence of an uncooperative attitude during the study.
  • Female volunteers in lactation.
  • Female volunteers who receive oral contraceptives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01017926

Sponsors and Collaborators
Pfizer
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01017926     History of Changes
Other Study ID Numbers: A6781002
Study First Received: November 20, 2009
Last Updated: August 5, 2010
Health Authority: Mexico: Ministry of Health

Keywords provided by Pfizer:
Triazolam bioequivalence

Additional relevant MeSH terms:
Triazolam
Adjuvants, Anesthesia
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014